

U.S. PATENT & TRADEMARK OFFICE
MAY 14 2004
JCI01056

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/773,806
Filing Date	02-06-2004
First Named Inventor	AUGUSTIN HITTINGER, ET AL
Group Art Unit	
Examiner Name	
Attorney Docket Number	FRAV2003/0004 - US - NP

Sheet	1	of	2	Attorney Docket Number	FRAV2003/0004 - US - NP
-------	---	----	---	------------------------	-------------------------

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴				
/MS/		WO	01/40218		MAILLIET, ET AL	06-07-2001	
↓		WO	02/055515		MAILLIET, ET AL	07-18-2002	
		WO	02/068408		MAILLIET, ET AL	09-06-2002	
		WO	02/076975		MAILLIET, ET AL	10-03-2002	
	/MS/	WO	02/096903		BOUCHARD, ET AL	12-05-2002	

Examiner Signature	/D Margaret Seaman/	Date Considered	12/10/2007
--------------------	---------------------	-----------------	------------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →

BEST AVAILABLE COPY

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

Complete if Known

Application Number	10/773,806
Filing Date	02-06-2004
First Named Inventor	AUGUSTIN HITTINGER, ET AL
Group Art Unit	
Examiner Name	
Attorney Docket Number	FRAV2003/0004 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MS/		B. F. CAIN et al., Potential Antitumour Agents. X. Bisquaternary Salts, Journal of Medicinal Chemical (1969, pp. 199-206, Volume 12, issue 2)	
/MS/		G. J. ATWELL et al., Potential Antitumor Agents. V. Bisquaternary Salts, Journal of Medicinal Chemistry (1967, pp. 706-713, Volume 41)	
/MS/		G. J. ATWELL et al., Potential Antitumor Agents. VI. Bisquaternary Salts, Journal of Medicinal Chemistry (1968, pp. 295-300, Volume 10, Issue 706)	
/MS/		LEONHARD KITTLER et al., Sequence Specific Modulation on DNA Restriction Enzyme Cleavage By Minor Groove Binders, Biol. Chem. (1998, pp. 519-525, Volume 379)	
/MS/		WILLIAM A. DENNY et al., Potential Antitumor Agents, 29. Quantitative Structure-Activity Relationships for the Antileukemic Bisquaternary Ammonium Heterocycles, Journal of Medicinal Chemistry (1979, pp. 134-150, Volume 22, Issue 2)	

Examiner
Signature

/D Margaret Seaman/

Date
Considered

12/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/773,806	
			Filing Date	02-06-2004	
			First Named Inventor	HITTINGER	
			Group Art Unit	1625	
			Examiner Name	Not Yet Known	
Sheet	1	of	4	Attorney Docket Number	FRAV2003/0004 - US - NP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/MS/ ↓		2003/0013711		MAILLIET	01-16-2003	
		2004/0053966		MAILLIET	03-18-2004	
		2005/0070571		MAILLIET	03-31-2005	
		5,767,278		GAETA et al	06-16-1998	
		5,770,613		GAETA et al	06-23-1998	
		5,854,244		JARMAN et al	12-29-1998	
		5,863,936		GAETA et al	01-26-1999	
		6,150,360		DAEYAERT et al	11-21-2000	
		6,262,053 B1		UCKUN et al	07-17-2001	
		6,362,210 B1		HAUEL et al	03-26-2002	
		6,645,964 B1		MAILLIET	11-11-2003	
		6,858,608		MAILLIET	02-22-2005	
		6,887,873		MAILLIET	05-03-2005	
		6,995,175		BOUCHARD	02-07-2006	
	/MS/	7,179,816		MAILLIET	02-20-2007	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
/MS/ ↓		CA	2 325 489		LEHR et al	09-30-1999	
		DE	198 12 879 A1		KIRSTEN et al	09-30-1999	
		DE	199 35 219 A1		HAUEL et al	02-01-2001	
		JP	11-60573		MASAYUKI et al	03-02-1999	
		JP	53-47439		SHIZUO et al	04-27-1978	
		JP	6-49062		KATSUTOSHI et al	02-22-1994	
		WO	01/07020 A2		HAUEL et al	02-01-2001	
		WO	01/19825 A1		DENNY et al	03-22-2001	
		WO	01/47897 A1		MORIARTY et al	07-05-2001	
	/MS/	WO	93/20056		JARMAN et al	10-14-1993	

Examiner Signature	/D Margaret Seaman/	Date Considered	12/10/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/773,806	
			Filing Date	02-06-2004	
			First Named Inventor	HITTINGER	
			Group Art Unit	1625	
			Examiner Name	Not Yet Known	
Sheet	2	of	4	Attorney Docket Number	FRAV2003/0004 - US - NP

[illegible][illegible]

Examiner Signature	/D Margaret Seaman/	Date Considered	12/10/2007
-----------------------	---------------------	--------------------	------------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/773,806
		Filing Date	02-06-2004
		First Named Inventor	HITTINGER
		Group Art Unit	1625
		Examiner Name	Not Yet Known
Sheet	3	of	4
		Attorney Docket Number	FRAV2003/0004 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MS/		BRATTAIN et al, Heterogeneity of Human Colon Carcinoma, Abstract of Cancer Metastasis Rev. 1984; 3(3):177-91	
/MS/		BURTON et al, Design of Novel Affinity Adsorbents for the Purification of trypsin-like Proteases, Abstract of J. Mol. Recognit. 1992, 5(2), pp. 55-68	
/MS/		CHEN et al, Spectroscopic Recognition of Guanine Dimeric Hairpin Quadruplexes by a Carbocyanine Dye, Proc. Natl. Acad. Sci. USA, Vol. 93, pp.2635-2639, April 1996	
/MS/		GILL, Surra. 3. Activity of Certain Derivatives of Acridine, Sulfonated Naphthylamine, aminoquinoline, styryl-quinoline, and Nitrofurazone Against Trypanosoma evansi in Rats, Abstract of Indian J. Anim. Sci., 1971, 41(6), pp. 503-9	
/MS/		HIRATANI et al, 2,6-Bis[N-(8-quinolyl)carbamoyl]pyridine as a Highly Selective Extractant for Cu(II), Bulletin of The Chemical Society of Japan, 1990, 63, pp. 3331-3333	
/MS/		KATSUTOSHI et al, Pyrimidinylamino-or Triazinylaminoquinoline Derivative and Its Production and Agricultural and Horticultural Germicide Containing the Same as Active Ingredient, Patent Abstracts of Japan, Publication No. 06049062 A, Publication Date Feb. 22, 1994	
/MS/		KREUTZBERGER et al, Synthesis And Spectroscopic Analyses Of Dianilnotriazines, English Language Abstract of Chemiker-Zeitung (1990, pp.208-210, volume 114)	
/MS/		KREUTZBERGER, ET AL, Synthesis And Spectroscopic Analyses Of Dianilnotriazines, Chemiker-Zeitung (1990, pp.208-210, volume 114)	
/MS/		MASAYUKI et al, Triazine Derivative and Telomerase Inhibitor, English Language Abstract of JP11-60573	
/MS/		MOKBEL et al, Telomerase and Breast Cancer: From Diagnosis to Therapy, Abstract of Int. J. Sug. Investig. 2000, 2(1), pp. 85-88	

Examiner Signature	/D Margaret Seaman/	Date Considered	12/10/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/773,806
		Filing Date	02-06-2004
		First Named Inventor	HITTINGER
		Group Art Unit	1625
		Examiner Name	Not Yet Known
Sheet	4	of	4
		Attorney Docket Number	FRAV2003/0004 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MS/		PANDYA et al, Studies on Potential Drugs : Potential Anthelmintics Part I, J. Inst. Chemists (India), Vol. XLVII, November 1975 pp. 235-237	
/MS/		SHIZUO et al, Coloring of High Molecular Weight Material, English Language Abstract of JP 53-47439	
/MS/		SUN et al, Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound, J. Med. Chem., 1997, 40, pp. 2113-2116	
/MS/		SWELLAM et al, Emerging role of p53, bcl-2 and Telomerase Activity in Egyptian Breast Cancer Patients, Abstract of IUBMB Life, 2004, 56(8), 483-490	
/MS/		WHEELHOUSE et al, Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA, J. Am. Chem. Soc., 1998, 120, pp. 3261-3262	
/MS/		WHITTEN et al, Rapid Microscale Synthesis, a New method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1 Receptor Antagonists, J. Med. Chem., 1996, 39, pp. 4354-4357	
/MS/		Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, Volume 1, 1004-1010, 1996	

Examiner Signature	/D Margaret Seaman/	Date Considered	12/10/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/773,806
		Filing Date	02-06-2004
		First Named Inventor	HITTINGER
		Group Art Unit	1625
		Examiner Name	SEAMAN, D. Margaret M.
Sheet 1 of 1	Attorney Docket Number	FRAV2003/0004 - US - NP	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MS/		BLASCO et al, Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA, Cell, 1997, 91, pp. 25-34	
/MS/		KIM et al, Specific Association of Human Telomerase Activity with Immortal Cells and Cancer, Science, 1994, 266, pp.2011-2015	
/MS/		LAVELLE, American Association for Cancer Research 1998: Promises and Prospects for the Next Century, Expert Opinion on Investigational Drugs, 1998, 7(6), pp. 1015-1021	
/MS/		MORIN, Is Telomerase a Universal Cancer Target?, Journal of the National Cancer Institute, 1995, 87 (12), pp.859-861	
/MS/		PERRY et al, Recent Advances in the Development of Telomerase Inhibitors for the Treatment of Cancer, Exp. Opin. Invest. Drugs (1999) 8(12), pp.1981-2008	
/MS/		SINGH et al, Antimalarials. "Distal" Hydrazine Derivatives of 7-Chloroquinoline, J. Med. Chem., 1971, 14(6), pp. 532-535	

Examiner Signature	/D Margaret Seaman/	Date Considered	12/10/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.